These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 20858176)

  • 1. Use of the adamantane structure in medicinal chemistry.
    Lamoureux G; Artavia G
    Curr Med Chem; 2010; 17(26):2967-78. PubMed ID: 20858176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adamantane - A Lead Structure for Drugs in Clinical Practice.
    Spilovska K; Zemek F; Korabecny J; Nepovimova E; Soukup O; Windisch M; Kuca K
    Curr Med Chem; 2016; 23(29):3245-3266. PubMed ID: 27222266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined action of ribovirin and rimantadine in experimental myxovirus infection.
    Galegov GA; Pushkarskaya NL; Obrosova-Serova NP; Zhdanov VM
    Experientia; 1977 Jul; 33(7):905-6. PubMed ID: 891769
    [No Abstract]   [Full Text] [Related]  

  • 4. [New adamantane derivatives and ways of overcoming the resistance of influenza A viruses to rimantadine and amantadine].
    Shibnev VA; Garayev TM; Finogenova MP; Shevchenko ES; Burtseva EI
    Vopr Virusol; 2011; 56(2):36-9. PubMed ID: 21545040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug resistance among influenza A viruses isolated in Italy from 2000 to 2005: are the emergence of Adamantane-resistant viruses cause of concern?
    Ansaldi F; Valle L; Amicizia D; Banfi F; Pastorino B; Sticchi L; Icardi G; Gasparini R; Crovari P
    J Prev Med Hyg; 2006 Mar; 47(1):1-3. PubMed ID: 17061402
    [No Abstract]   [Full Text] [Related]  

  • 6. [Synthesis and in vitro virucidal effect of recent 1-substituted adamantane derivatives].
    Sztaricskai F; Pelyvás I; Dinya Z; Szilágyi L; Györgydeák Z; Hadházy G; Váczi L; Bognár R
    Pharmazie; 1975 Sep; 30(9):571-81. PubMed ID: 1187737
    [No Abstract]   [Full Text] [Related]  

  • 7. Synthesis and pharmacological evaluation of (2-oxaadamant-1-yl)amines.
    Duque MD; Camps P; Profire L; Montaner S; Vázquez S; Sureda FX; Mallol J; López-Querol M; Naesens L; De Clercq E; Prathalingam SR; Kelly JM
    Bioorg Med Chem; 2009 Apr; 17(8):3198-206. PubMed ID: 19251424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel adamantane derivatives act as blockers of open ligand-gated channels and as anticonvulsants.
    Antonov SM; Johnson JW; Lukomskaya NY; Potapyeva NN; Gmiro VE; Magazanik LG
    Mol Pharmacol; 1995 Mar; 47(3):558-67. PubMed ID: 7535380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives.
    Wanka L; Iqbal K; Schreiner PR
    Chem Rev; 2013 May; 113(5):3516-604. PubMed ID: 23432396
    [No Abstract]   [Full Text] [Related]  

  • 10. Specific inhibitors of influenza virus replication as potential chemoprophylactic agents.
    Oxford JS
    J Antimicrob Chemother; 1975 Mar; 1(1):7-23. PubMed ID: 1100585
    [No Abstract]   [Full Text] [Related]  

  • 11. Two blocking sites of amino-adamantane derivatives in open N-methyl-D-aspartate channels.
    Sobolevsky A; Koshelev S
    Biophys J; 1998 Mar; 74(3):1305-19. PubMed ID: 9512028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Synthesis of derivatives of N-(1-adamantyl)-N'-urea with potential antiviral activity].
    Skwarski D; Maliszewska H
    Acta Pol Pharm; 1988; 45(5):391-4. PubMed ID: 3247849
    [No Abstract]   [Full Text] [Related]  

  • 13. [Structure and antiviral activity of adamantane-containing polymer preparation].
    Kozeletskaia KN; Stotskaia LL; Serbin AV; Munshi K; Sominina AA; Kiselev OI
    Vopr Virusol; 2003; 48(5):19-26. PubMed ID: 14598476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Development of novel drugs against influenza virus based on synthetic and natural compounds].
    Zarubaev VV; Anfimov PM; Shtro AA; Garshinina AV; Meleshkina IA; Karpinskaia LA; Kozeletskaia KN; Kiselev OI
    Vopr Virusol; 2012; 57(6):30-6. PubMed ID: 23477252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High levels of adamantane resistance among influenza A (H3N2) viruses and interim guidelines for use of antiviral agents--United States, 2005-06 influenza season.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2006 Jan; 55(2):44-6. PubMed ID: 16424859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral drugs for influenza.
    Med Lett Drugs Ther; 2011 Jan; 53(1355):1-3. PubMed ID: 21212742
    [No Abstract]   [Full Text] [Related]  

  • 17. New adamantane derivatives can overcome resistance of influenza A(H1N1)pdm2009 and A(H3N2) viruses to remantadine.
    Shibnev VA; Garaev TM; Finogenova MP; Shevchenko ES; Burtseva EI
    Bull Exp Biol Med; 2012 Jun; 153(2):233-5. PubMed ID: 22816091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Susceptibility of antiviral drugs against 2009 influenza A (H1N1) virus.
    Rungrotmongkol T; Intharathep P; Malaisree M; Nunthaboot N; Kaiyawet N; Sompornpisut P; Payungporn S; Poovorawan Y; Hannongbua S
    Biochem Biophys Res Commun; 2009 Jul; 385(3):390-4. PubMed ID: 19463784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to anti-influenza drugs: adamantanes and neuraminidase inhibitors.
    Hurt AC; Ho HT; Barr I
    Expert Rev Anti Infect Ther; 2006 Oct; 4(5):795-805. PubMed ID: 17140356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adamantylthiourea derivatives as antiviral agents.
    Tilley JW; Levitan P; Kramer MJ
    J Med Chem; 1979 Aug; 22(8):1009-10. PubMed ID: 490532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.